AIDX 20/20 Biolabs, Inc.

0.3435USD-2.53%Mkt Cap: 4.39M $P/E: —

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detect…

Key Statistics

Company
Market Cap4.39M USD
Enterprise Value2.07M USD
Revenue (TTM)2.04M USD
Gross Profit604.54K USD
Net Income (TTM)-3.74M USD
Revenue/Share0.29 USD
Last Price0.3435 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.48
EV/Revenue1.01
P/S2.21
P/B2.67
EPS (TTM)-0.75
EPS (Forward)—
52W Range
0.33100% of range50.00
52W High50.00 USD
52W Low0.3310 USD
Profitability
Gross Margin29.56%
Oper. Margin-170.31%
EBITDA Margin-211.83%
Profit Margin-182.82%
ROE19447.70%
ROA-90.37%
Growth
Revenue Growth36.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.92M USD
CapEx (TTM)—
FCF Margin-39.49%
FCF Yield-18.37%
Net Debt-3.97M USD
Net Debt/EBITDA0.92
Balance Sheet
Debt/Equity-70.67
Current Ratio1.99
Quick Ratio1.90
Book Value/Sh0.13 USD
Cash/Share0.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.000 USD
Upside (mean)+1355.6%
Target Range5.000 USD – 5.000 USD
# Analysts1
Ownership
Shares Out.12.77M
Float10.85M
Insiders20.40%
Institutions4.23%
Short Interest
Short Ratio0.6d
Short % Float0.44%
Short % Out.0.37%
Shares Short46.81K
Short (prev mo.)105.84K
Technical
SMA 500.4938 (-30.4%)
SMA 2001.484 (-76.9%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)62.20K
Avg Vol (10d)67.58K
Technical Indicators
RSI (14)26.3
MACD-0.0468
MACD Signal-0.0372
MACD Hist.-0.0096
BB Upper0.5623 USD
BB Middle0.4416 USD
BB Lower0.3210 USD
BB Width54.63%
ATR (14)0.0482 USD
Vol Ratio (20d)1.44x